目的 探討津力達(dá)顆粒聯(lián)合度拉糖肽注射液治療2型糖尿病臨床療效。方法 選取2019年6月-2020年3月河南理工大學(xué)第一附屬醫(yī)院收治的2型糖尿病患者92例，根據(jù)用藥的差別分成對照組（46例）和治療組（46例）。對照組靜脈滴注度拉糖肽注射液，起始劑量0.75 mg/周，最大劑量1.5 mg/周；治療組在對照組的基礎(chǔ)上口服津力達(dá)顆粒，9 g/次，3次/d。兩組患者均經(jīng)8周治療。觀察兩組患者臨床療效，同時比較治療前后兩組患者空腹血糖（FPG）、糖化血紅蛋白（HbA1c）、餐后2 h血糖（2 h PG）和胰島素（FINS）水平，血糖波動情況，及血清單核細(xì)胞趨化蛋白1（MCP-1）、γ-谷氨酰轉(zhuǎn)移酶（γ-GT）、血管細(xì)胞黏附分子1（VCAM-1）、白細(xì)胞介素-1β（IL-1β）和瘦素（LP）水平。結(jié)果 治療后，對照組臨床有效率為80.43%，顯著低于治療組的97.87%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者FPG、HbAlc、2 h PG、FINS、血糖波動指標(biāo)，及血清MCP-1、γ-GT、VCAM-1、IL-1β和LP水平均顯著降低（P<0.05），且治療組患者明顯低于對照組（P<0.05）。結(jié)論 津力達(dá)顆粒聯(lián)合度拉糖肽注射液治療2型糖尿病可有效控制患者血糖水平，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the therapeutic effect of Jinlida Granules combined with dulaglutide in treatment of type 2 diabetes mellitus. Methods Patients (92 cases) with type 2 diabetes mellitus in the First Affiliated Hospital of Henan Polytechnic University from June 2019 to March 2020 were divided into control (46 cases) and treatment (46 cases) groups based on different treatments. Patients in the control group were iv administered with Dulaglutide Injection, the initial dose was 0.75 mg/week, and the maximum dose was 1.5 mg/week. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 9 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the level of FPG, HbA1c, 2 h PG, FINS, blood glucose fluctuation, and the serum content of MCP-1, γ-GT, VCAM-1, IL-1β and LP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.43%, which was significantly lower than 97.87% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the level of FPG, HbA1c, 2 h PG, FINS, blood glucose fluctuation, and the serum content of MCP-1, γ-GT, VCAM-1, IL-1β and LP in two groups were significantly decreased (P < 0.05), and these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jinlida Granules combined with dulaglutide in treatment of type 2 diabetes mellitus can effectively control the blood glucose level, which has a certain clinical application value.

R977

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20191356）